533 related articles for article (PubMed ID: 30925125)
21. Exploratory phase II trial in a multicenter setting to evaluate the clinical value of a chemosensitivity test in patients with gastric cancer (JACCRO-GC 04, Kubota memorial trial).
Tanigawa N; Yamaue H; Ohyama S; Sakuramoto S; Inada T; Kodera Y; Kitagawa Y; Omura K; Terashima M; Sakata Y; Nashimoto A; Yamaguchi T; Chin K; Nomura E; Lee SW; Takeuchi M; Fujii M; Nakajima T
Gastric Cancer; 2016 Apr; 19(2):350-360. PubMed ID: 26385385
[TBL] [Abstract][Full Text] [Related]
22. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
Oki E; Murata A; Yoshida K; Maeda K; Ikejiri K; Munemoto Y; Sasaki K; Matsuda C; Kotake M; Suenaga T; Matsuda H; Emi Y; Kakeji Y; Baba H; Hamada C; Saji S; Maehara Y
Ann Oncol; 2016 Jul; 27(7):1266-72. PubMed ID: 27056996
[TBL] [Abstract][Full Text] [Related]
23. Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study.
Kodera Y; Yoshida K; Kochi M; Sano T; Ichikawa W; Kakeji Y; Sunakawa Y; Takeuchi M; Fujii M
Gastric Cancer; 2023 Nov; 26(6):1063-1068. PubMed ID: 37548812
[TBL] [Abstract][Full Text] [Related]
24. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
[TBL] [Abstract][Full Text] [Related]
25. [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
Zhou Y; Huang J; Yang L; Chi Y; Qu T; Lü X; Wang JW
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):860-4. PubMed ID: 23291138
[TBL] [Abstract][Full Text] [Related]
26. [Adjuvant chemotherapy with S-1 plus docetaxel for highly advanced gastric cancer patients].
Egawa T; Kemmochi T; Irino T; Mihara K; Okamura A; Etoh E; Inaba Y; Segami K; Ito Y; Nagashima A
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2310-2. PubMed ID: 23268060
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer.
Kochi M; Fujii M; Kanamori N; Kaiga T; Takahashi T; Kobayashi M; Takayama T
J Cancer Res Clin Oncol; 2006 Dec; 132(12):781-5. PubMed ID: 16804723
[TBL] [Abstract][Full Text] [Related]
28. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.
Ito S; Sano T; Mizusawa J; Takahari D; Katayama H; Katai H; Kawashima Y; Kinoshita T; Terashima M; Nashimoto A; Nakamori M; Onaya H; Sasako M
Gastric Cancer; 2017 Mar; 20(2):322-331. PubMed ID: 27299887
[TBL] [Abstract][Full Text] [Related]
29. A Phase 2 Study of Induction Chemotherapy Using Docetaxel, Cisplatin, and S-1 for Gastric Cancer with Peritoneal Metastasis (KUGC06).
Okabe H; Hata H; Hosogi H; Ueda S; Ota S; Kinjo Y; Hoshino N; Hisamori S; Tsunoda S; Obama K; Sakai Y;
Ann Surg Oncol; 2019 Jun; 26(6):1779-1786. PubMed ID: 30767179
[TBL] [Abstract][Full Text] [Related]
30. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
[TBL] [Abstract][Full Text] [Related]
31. Short-term results of a phase II study of preoperative docetaxel/cisplatin/S-1 therapy for locally advanced gastric cancer.
Tsuchida K; Sato T; Aoyama T; Atsumi Y; Kano K; Maezawa Y; Kazama K; Numata M; Yamada T; Tamagawa H; Murakami H; Oshima T; Saeki H; Cho H; Yukawa N; Yamamoto Y; Masuda M; Rino Y
Jpn J Clin Oncol; 2021 Mar; 51(3):371-378. PubMed ID: 33283236
[TBL] [Abstract][Full Text] [Related]
32. A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study).
Kagawa S; Muraoka A; Kambara T; Nakayama H; Hamano R; Tanaka N; Noma K; Tanakaya K; Kishimoto H; Shigeyasu K; Kuroda S; Kikuchi S; Kuwada K; Nishizaki M; Shirakawa Y; Fujiwara T
Cancer Chemother Pharmacol; 2018 Feb; 81(2):387-392. PubMed ID: 29290024
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy and safety of S-1 plus docetaxel combination therapy for patients with advanced gastric cancer].
Nishiwaki H; Yamada T; Tachi K; Iwasaki H; Hori Y; Umemura S; Yamakawa Y; Kurimoto T; Ban T; Fujiwara K; Hayashi K; Nemoto A; Shiroko J; Orito E
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1663-6. PubMed ID: 19838024
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of docetaxel and S-1 (DS) as neoadjuvant chemotherapy for clinical stage III resectable gastric cancer.
Oki E; Emi Y; Kusumoto T; Sakaguchi Y; Yamamoto M; Sadanaga N; Shimokawa M; Yamanaka T; Saeki H; Morita M; Takahashi I; Hirabayashi N; Sakai K; Orita H; Aishima S; Kakeji Y; Yamaguchi K; Yoshida K; Baba H; Maehara Y
Ann Surg Oncol; 2014 Jul; 21(7):2340-6. PubMed ID: 24604583
[TBL] [Abstract][Full Text] [Related]
35. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
Tanabe K; Fujii M; Nishikawa K; Kunisaki C; Tsuji A; Matsuhashi N; Takagane A; Ohno T; Kawase T; Kochi M; Yoshida K; Kakeji Y; Ichikawa W; Chin K; Terashima M; Takeuchi M; Nakajima T
Ann Oncol; 2015 Sep; 26(9):1916-1922. PubMed ID: 26109630
[TBL] [Abstract][Full Text] [Related]
36. Feasibility study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer: a randomized controlled trial.
Tatebe S; Tsujitani S; Nakamura S; Shimizu T; Yamane N; Nishidoi H; Kurisu Y; Kanayama H; Ogawa H; Ikeguchi M
Gastric Cancer; 2014; 17(3):508-13. PubMed ID: 23948997
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of combination therapy with S-1 and docetaxel (TXT) for advanced or recurrent gastric cancer.
Yoshida K; Hirabayashi N; Takiyama W; Ninomiya M; Takakura N; Sakamoto J; Nishiyama M; Toge T
Anticancer Res; 2004; 24(3b):1843-51. PubMed ID: 15274365
[TBL] [Abstract][Full Text] [Related]
38. A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC).
Ueda Y; Fujimura T; Kinami S; Hirono Y; Yamaguchi A; Naitoh H; Tani T; Kaji M; Yamagishi H; Miwa K;
Jpn J Clin Oncol; 2006 Aug; 36(8):519-22. PubMed ID: 16803844
[TBL] [Abstract][Full Text] [Related]
39. A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine.
Lee KW; Kim BJ; Kim MJ; Han HS; Kim JW; Park YI; Park SR
Cancer Res Treat; 2017 Jul; 49(3):706-716. PubMed ID: 27764906
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]